Prostate Cancer
The most common cancer affecting the male reproductive system, ranging from slow-growing tumors managed with surveillance to aggressive disease requiring multimodal treatment.
- PSA and biopsy-based diagnosis
- Gleason grading and risk grouping
- Surgery, radiation, and hormonal therapy
- Genomic and biomarker testing
- Most Common In
- Men over 50
- Key Marker
- PSA (Prostate-Specific Antigen)
- Grading System
- Gleason Score / Grade Groups
- Treatment Range
- Surveillance to multimodal therapy
- Advanced Therapies
- PARP inhibitors, PSMA-targeted therapy
Condition Overview
Prostate cancer develops in the prostate gland, a small organ that produces seminal fluid. It is one of the most commonly diagnosed cancers in men, with a wide range of behavior — from slow-growing tumors that may never cause symptoms to aggressive forms that spread beyond the prostate. Outcomes depend heavily on grade, stage, and genomic features at diagnosis.
Types and Subtypes
Prostate cancer is classified by histologic subtype and by molecular features that increasingly inform treatment selection.
Symptoms and Signs
Early prostate cancer is often asymptomatic and detected through PSA screening. Symptoms tend to appear as the tumor grows or spreads.
Causes and Risk Factors
The exact cause of prostate cancer is not fully understood, but several risk factors are well established.
Diagnosis and Investigations
Diagnosis combines blood testing, imaging, and tissue biopsy, increasingly supported by genomic profiling.
Staging and Risk Groups
Prostate cancer is staged using the TNM system and stratified into risk groups based on PSA, Gleason/Grade Group, and clinical stage to guide treatment decisions.
Standard Treatment
Treatment selection depends on risk group, life expectancy, and patient preference, ranging from observation to combined local and systemic therapy.
Advanced & Emerging Therapies
Newer targeted and radioligand therapies are expanding options for advanced or treatment-resistant prostate cancer.
PARP Inhibitor Therapy
PARP inhibitors for BRCA-mutated disease
Targeted therapy for patients with BRCA1/BRCA2 or other homologous recombination repair mutations.
Radioligand Therapy
PSMA-targeted radioligand therapy
Delivers targeted radiation to PSMA-expressing prostate cancer cells in metastatic castration-resistant disease.
Immunotherapy
Checkpoint inhibitors for select biomarker-positive tumors
Considered in tumors with specific markers such as high microsatellite instability.
Clinical Trial Options
Novel androgen receptor degraders and combination regimens
Investigational approaches being studied for resistant or progressive disease, including access through international trial networks.
Biomarkers & Precision Medicine
Genomic and protein biomarkers increasingly guide risk assessment and targeted treatment selection in prostate cancer.
When to Seek a Second Opinion
Given the range of treatment paths available, a second opinion can help clarify the most appropriate option for an individual's risk profile and goals.
Clinical Trials & Research
Prognosis & Outcomes
Prognosis in prostate cancer varies widely by risk group, with many localized cases having a favorable long-term outlook, while advanced or treatment-resistant disease requires ongoing systemic management.
Supportive Care
Supportive care addresses treatment side effects and helps maintain quality of life throughout the prostate cancer journey.
How CancerFax Helps You Explore Treatment Options
CancerFax helps men with prostate cancer review PSA and biopsy results, connect with urologic and radiation oncology specialists, and explore advanced therapy or clinical trial options, including international second opinions.
Get a free case reviewFrequently Asked Questions
Prostate cancer is a malignancy that develops in the prostate gland, ranging from slow-growing tumors to more aggressive disease that can spread beyond the prostate.
Early prostate cancer often causes no symptoms and is detected through PSA screening. When symptoms occur, they often involve urinary changes such as difficulty starting urination or a weak stream.
An elevated PSA can indicate prostate cancer but can also result from benign conditions such as an enlarged prostate or infection, so further testing is typically needed to clarify the cause.
The Gleason score grades how abnormal prostate cancer cells appear under a microscope, with higher scores indicating more aggressive disease and informing treatment decisions.
For carefully selected low-risk patients, active surveillance with regular monitoring is considered a safe approach that can delay or avoid treatment-related side effects.
Advanced prostate cancer may be treated with androgen deprivation therapy, chemotherapy, androgen receptor pathway inhibitors, PARP inhibitors for select mutations, or PSMA-targeted radioligand therapy.
Testing for BRCA1/BRCA2 and other mutations can identify candidates for targeted therapies such as PARP inhibitors and inform family risk counseling.
This refers to prostate cancer that continues to progress despite low testosterone levels from hormonal therapy, often requiring additional systemic treatment approaches.
Staging combines PSA level, Gleason score/Grade Group, and imaging findings using the TNM system to classify disease as localized, locally advanced, or metastatic.
Yes. CancerFax helps review PSA, biopsy, and imaging reports, coordinates second opinions with urologic and radiation oncology specialists, and supports access to advanced therapies, clinical trials, and international treatment centers, including China-based options.
Get Expert Guidance on Your Prostate Cancer Diagnosis
Share your PSA results, biopsy report, and imaging to explore treatment options, second opinions, and access to specialist centers.